In summary, X-370 functions as a novel PI3Kδ inhibitor with promising activity against B-ALL cells displaying PI3Kδ-dependent Erk1/2 signaling via an atypical PI3K-PDK1-MEK1/2-Erk1/2 signaling cascade. The gene discussed is MAP2K1; the disease is acute lymphoblastic leukemia.